Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Equity Average (2018 - 2025)

Eton Pharmaceuticals' Equity Average history spans 7 years, with the latest figure at $24.6 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 21.95% to $24.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.6 million, a 21.95% increase, with the full-year FY2025 number at $25.3 million, up 26.76% from a year prior.
  • Equity Average hit $24.6 million in Q4 2025 for Eton Pharmaceuticals, up from $23.5 million in the prior quarter.
  • Over the last five years, Equity Average for ETON hit a ceiling of $24.6 million in Q4 2025 and a floor of $12.1 million in Q4 2022.
  • Historically, Equity Average has averaged $17.5 million across 5 years, with a median of $16.4 million in 2021.
  • Biggest five-year swings in Equity Average: surged 332.31% in 2021 and later crashed 37.04% in 2022.
  • Tracing ETON's Equity Average over 5 years: stood at $16.6 million in 2021, then dropped by 27.13% to $12.1 million in 2022, then soared by 33.43% to $16.2 million in 2023, then increased by 24.84% to $20.2 million in 2024, then rose by 21.95% to $24.6 million in 2025.
  • Business Quant data shows Equity Average for ETON at $24.6 million in Q4 2025, $23.5 million in Q3 2025, and $24.2 million in Q2 2025.